Related Experiment Video

Updated: Jul 9, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

ERK-dependent MKP-1-mediated cisplatin resistance in human ovarian cancer cells

Juan Wang1, Jun-Ying Zhou, Gen Sheng Wu

  • 1Program in Molecular Biology and Genetics, Karmanos Cancer Institute, Department of Pathology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA.

Cancer Research
|December 20, 2007
PubMed

Insights

Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression, driven by ERK2, is crucial for cisplatin resistance in ovarian cancer. Targeting this ERK-MKP-1 pathway may overcome resistance.

Area of Science:

  • Molecular Biology
  • Cancer Research
  • Cell Signaling

Background:

  • Mitogen-activated protein kinase (MAPK) phosphatase-1 (MKP-1) negatively regulates MAPK signaling.
  • MKP-1 has been implicated in cisplatin resistance, but the underlying mechanisms remain unclear.
  • Understanding MKP-1's role is vital for developing effective ovarian cancer treatments.

Purpose of the Study:

  • To elucidate the mechanism by which MKP-1 contributes to cisplatin resistance in human ovarian cancer cells.
  • To investigate the role of ERK2 signaling in the induction of MKP-1 by cisplatin.
  • To explore the potential of targeting the ERK-MKP-1 pathway to overcome cisplatin resistance.

Main Methods:

  • Utilized human ovarian cancer cell lines.
  • Investigated MKP-1 induction via phosphorylation following cisplatin treatment.
  • Employed MEK1/2 inhibitor (U0126) and small interfering RNA (siRNA) for ERK2 and MKP-1 down-regulation.
  • Assessed cisplatin-induced cell death, apoptosis, and Bcl-2 protein levels.

Main Results:

  • Cisplatin induces MKP-1 expression through phosphorylation, dependent on ERK2 activity.
  • Inhibition of ERK2 or MKP-1 enhances cisplatin-induced cell death and apoptosis.
  • Down-regulation of ERK2 or MKP-1 reduces basal Bcl-2 protein levels.
  • Inhibition of Bcl-2 sensitizes ovarian cancer cells to cisplatin.

Conclusions:

  • Cisplatin resistance in ovarian cancer is mediated by ERK2-dependent induction of MKP-1.
  • The ERK-MKP-1 signaling pathway plays a critical role in conferring cisplatin resistance.
  • Targeting the ERK-MKP-1 pathway presents a promising strategy to overcome cisplatin resistance in human ovarian cancer.

More Related Videos

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines11:50

Enrichment for Chemoresistant Ovarian Cancer Stem Cells from Human Cell Lines

Published on: September 10, 2014

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...